Warnings & Recalls for Vyvanse
Family Planning Warning
Vyvanse is a FDA pregnancy category C drug, meaning there is no controlled data on its effects on pregancy. Patients should only take this drug if the benefits to the mother outweigh potential harm to the fetus. Amphetamines are excreted into human milk, however long term effects to the infant are unknown. The decision should be made whether to discontinue the drug or discontinue breastfeeding.
General Warnings
Vyvanse may cause
sudden death in patients with cardiovascular illness,
new or worsened psychotic conditions and growth suppression in children.
Patients are advised to notify their doctors if they have any of the following conditions:
- a history of drug abuse.
- suicidal thoughts
- cardiovascular conditions
Vyvanse Interactions
- Alkalinizing and Acidifying Agents
- Monoamine Oxidase Inhibitors
Vyvanse Treatment and Use
What is Vyvanse?
Vyvanse | lisdexamphetamine is drug made by Shire US Inc, that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children 6-12 as well as adults 18 and older. It is used as part of a treatment program that may include cognitive and behavioral therapy as well as other pharmacological treatments.
How does Vyvanse work?
In the body, Vyvanse’s active incredient, lisdexamphetamine, is changed to dextroamphetamine, a stimulant. Although one would think that dextroamphetamine would cause hyperactivity, this drug has a calming effect on persons being treated with it. It is unknown how or why this occurs.
Vyvanse dosing
Vyvanse comes in capsule form and should be taken orally once daily in the morning with or without food.
For children and adults being treated for ADHD, the recommended starting dose of Vyvanse is 30 mg once daily in the morning. The medication can be increased to a maximum of 60 mg per day.
It is unknown how this medication effects adolescents as no Vyvanse studies have been conducted on this particular age group.
